Literature DB >> 1327002

Erythrocyte membrane sodium-potassium adenosine triphosphatase activity in affective disorders.

P L Reddy1, S Khanna, M N Subhash, S M Channabasavanna, B S Rao.   

Abstract

Erythrocyte membrane Na+,K(+)-ATPase activity was studied in drug naive patients with bipolar (BP) mania (n = 62) and unipolar (UP) depression (n = 60) and normal controls (n = 66). Compared to controls there was a significantly decreased Na+,K(+)-ATPase activity in UP depressives but no change in BP manics. However, lithium treatment caused a significant increase in Na+,K(+)-ATPase activity although there was no correlation between plasma lithium levels and enzyme activity. Plasma cortisol correlated inversely with Na+,K(+)-ATPase in UP depressives. Interestingly, the lithium responders [less than 50% Beck Rafaelson's Mania Rating Scale (BRMS) score] showed a significant increase in Na+,K(+)-ATPase activity compared to lithium nonresponders (greater than 50% BRMS score). These observations indicate that monitoring of Na+,K(+)-ATPase activity during lithium therapy is useful to predict a therapeutic response.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1327002     DOI: 10.1007/bf01250673

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  36 in total

Review 1.  Alterations in cell membrane activity in depression.

Authors:  J Mendels; A Frazer
Journal:  Am J Psychiatry       Date:  1974-11       Impact factor: 18.112

2.  Erythrocyte membrane cation carrier in depressive illness.

Authors:  G J Naylor; D A Dick; E G Dick; D Le Poidevin; S F Whyte
Journal:  Psychol Med       Date:  1973-11       Impact factor: 7.723

3.  Measurement of inorganic orthophosphate in biological materials: extraction properties of butyl acetate.

Authors:  H Sanui
Journal:  Anal Biochem       Date:  1974-08       Impact factor: 3.365

Review 4.  Pathological alterations of cation movements in red blood cells.

Authors:  J C Parker; L G Welt
Journal:  Arch Intern Med       Date:  1972-02

5.  Sodium balance and distribution in lithium carbonate therapy.

Authors:  L Baer; J Durell; W E Bunney; B S Levy; D L Murphy; K Greenspan; P V Cardon
Journal:  Arch Gen Psychiatry       Date:  1970-01

6.  Sodium transfer from plasma to CSF in severe depressive illness.

Authors:  B J Carroll; L Steven; R A Pope; B Davies
Journal:  Arch Gen Psychiatry       Date:  1969-07

7.  A single reagent method of phosphate estimation in phosphatase(s) assay.

Authors:  M K Sapru; H Geetha; K T Shetty
Journal:  Indian J Biochem Biophys       Date:  1987-12       Impact factor: 1.918

8.  The effects of lithium treatment on cation transport processes in erythrocytes of patients with affective illnesses.

Authors:  J Rybakowski; E Potok; W Strzyzewski; M Chłopocka-Woźniak
Journal:  Pol J Pharmacol Pharm       Date:  1983 May-Jun

9.  Red cell ouabain-sensitive Na+-K+-adenosine triphosphatase: a state marker in affective disorder inversely related to plasma cortisol.

Authors:  J Nurnberger; D C Jimerson; J R Allen; S Simmons; E Gershon
Journal:  Biol Psychiatry       Date:  1982-09       Impact factor: 13.382

10.  Effect of electroconvulsive therapy on erythrocyte adenosine triphosphatase activity in depressive illness.

Authors:  L J Whalley; M Scott; H W Reading; J E Christie
Journal:  Br J Psychiatry       Date:  1980-10       Impact factor: 9.319

View more
  3 in total

Review 1.  Endogenous digitalis-like Na+, K+-ATPase inhibitors, and brain function.

Authors:  D Lichtstein; H Rosen
Journal:  Neurochem Res       Date:  2001-09       Impact factor: 3.996

2.  Reduction of hippocampal Na+, K+-ATPase activity in rats subjected to an experimental model of depression.

Authors:  Giovana D Gamaro; Emilio L Streck; Cristiane Matté; Martha E Prediger; Angela T S Wyse; Carla Dalmaz
Journal:  Neurochem Res       Date:  2003-09       Impact factor: 3.996

Review 3.  Lithium in the treatment of bipolar disorder: pharmacology and pharmacogenetics.

Authors:  M Alda
Journal:  Mol Psychiatry       Date:  2015-02-17       Impact factor: 15.992

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.